

**In the Claims:**

1. (Currently Amended) A co-crystal of mammalian Glucokinase (Seq ID NO:1) and a ligand bound to an allosteric site of the Glucokinase, wherein

the co-crystal has unit cell dimensions of:

a and b are from ~~about~~ 79 Å to ~~about~~ 80.2 Å;

c is from ~~about~~ 318 Å to ~~about~~ 325 Å;

$\alpha$  and  $\beta$  are 90°; and

$\gamma$  is 120°;

and the co-crystal has P6(5)22 symmetry.

2. (Currently Amended) A crystal of mammalian Glucokinase (Seq ID NO:1), wherein the crystal has unit cell dimensions of:

a and b are from ~~about~~ 79 Å to ~~about~~ 80.2 Å;

c is from ~~about~~ 318 Å to ~~about~~ 325 Å;

$\alpha$  and  $\beta$  are 90°; and

$\gamma$  is 120°;

and the crystal has P6(5)22 symmetry.

3. (Currently Amended) A process for co-crystalizing mammalian Glucokinase (Seq ID NO:1) and an allosteric ligand of Glucokinase, the process comprising:

providing a buffered, aqueous solution of ~~about~~ 9 to ~~about~~ 22 mg/ml of the mammalian Glucokinase (Seq ID NO:1);

adding a molar excess of the allosteric ligand to the aqueous solution of mammalian Glucokinase; and

growing crystals by vapor diffusion using a buffered reservoir solution of ~~about~~ 16% to about 25% PEG, ~~about~~ 0% w/v to ~~about~~ 30% w/v glucose and ~~about~~ 8 to ~~about~~ 10 mM DTT, wherein the PEG has an average molecular weight of about 8,000 to about 10,000.

4. (Currently Amended) The process of claim 3, wherein the step of growing crystals by vapor diffusion comprises:

streaking the buffered, aqueous solution of mammalian Glucokinase (Seq ID NO:1) with added allosteric ligand on a surface to form an elongated droplet of protein solution, and

streaking about an equal amount of the buffered reservoir solution across the elongated droplet of protein solution, forming a combined droplet shaped like the letter 'X'.